{"created":"2023-06-19T10:37:43.252148+00:00","id":1828,"links":{},"metadata":{"_buckets":{"deposit":"c597d518-8aaa-460c-8025-df30f0b6a957"},"_deposit":{"created_by":16,"id":"1828","owners":[16],"pid":{"revision_id":0,"type":"depid","value":"1828"},"status":"published"},"_oai":{"id":"oai:iwate-pu.repo.nii.ac.jp:00001828","sets":["19:20:274"]},"author_link":["3433","3434","3435","3436"],"item_7_biblio_info_12":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2011-01-01","bibliographicIssueDateType":"Issued"},"bibliographicPageEnd":"20","bibliographicPageStart":"13","bibliographicVolumeNumber":"13","bibliographic_titles":[{"bibliographic_title":"岩手県立大学看護学部紀要","bibliographic_titleLang":"ja"},{"bibliographic_title":"Journal of the Faculty of Nursing, Iwate Prefectural University","bibliographic_titleLang":"en"}]}]},"item_7_description_10":{"attribute_name":"抄録(日)","attribute_value_mlt":[{"subitem_description":"C型慢性肝炎例でpeginterferon治療(ribavirin併用例を含む)受けた19例を対象とし、治療開始時から経時的にALT、HCV-RNA、anti-HCV core titerを測定した。anti-HCV core titerは、peginterferon・ribavirin併用療法群およびpeginterferon monotherapy療法群とも、SVR例では治療開始後から持続して減少し、治療終了時には減少率は50%に達し、治療終了後はさらに減少を示した。一方non SVR例では、治療開始後も減少傾向は明らかではなく、治療終了後は逆に増加を示した。またSVR例13例中12例がEVRであったことから、EVRで治療中anti-HCV core titerが持続減少を示す場合には、peginterferon・ribavirin併用療法例、peginterferon monotherapy療法例とも治療期間の短縮を考慮することが可能と考えられる。このことはリスク背景を有するC型慢性肝炎例に対して、不要な継続治療を避けより適切なpeginterferonの治療法および治療期間の選択に貢献するものである。","subitem_description_type":"Other"}]},"item_7_description_11":{"attribute_name":"抄録(英)","attribute_value_mlt":[{"subitem_description":"Serial measurements of ALT, HCV-RNA and anti-HCV core titer were made from the start of therapy in 19 patients undergoing treatment with peginterferon (including combined therapy with ribavirin) for chronic hepatitis C. Anti-HCV core titer in SVR patients in both the peginterferon and ribavirin combination therapy group and the peginterferon monotherapy group fell continuously from the start of therapy, with the rate of decrease reaching 50% at the end of therapy, and continued to fall after the therapy ended. In non-SVR patients, there was no clear decrease after the start of therapy, and the anti-HCV core titer rose after the end of therapy. In addition, as 12 of 13 SVR patients were EVR, it appears that shortening the therapy period can be considered for both peginterferon and ribavirin combination therapy and peginterferon monotherapy when the patient shows EVR and the anti-HCV core titer decreases continuously during therapy. By avoiding unnecessary continuous treatment, more appropriate peginterferon therapy methods and administration periods can be used when treating chronic hepatitis C in patients with background risk factors.","subitem_description_type":"Other"}]},"item_7_description_15":{"attribute_name":"表示順","attribute_value_mlt":[{"subitem_description":"4","subitem_description_type":"Other"}]},"item_7_description_16":{"attribute_name":"アクセション番号","attribute_value_mlt":[{"subitem_description":"KJ00008027239","subitem_description_type":"Other"}]},"item_7_description_8":{"attribute_name":"記事種別(日)","attribute_value_mlt":[{"subitem_description":"原著 ","subitem_description_type":"Other"}]},"item_7_source_id_1":{"attribute_name":"雑誌書誌ID","attribute_value_mlt":[{"subitem_source_identifier":"AA11373559","subitem_source_identifier_type":"NCID"}]},"item_7_source_id_19":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"13449745","subitem_source_identifier_type":"PISSN"}]},"item_7_text_7":{"attribute_name":"著者所属(英)","attribute_value_mlt":[{"subitem_text_language":"en","subitem_text_value":"Faculty of Nursing, Iwate Prefectural University"},{"subitem_text_language":"en","subitem_text_value":"Faculty of Nursing, Iwate Prefectural University"},{"subitem_text_language":"en","subitem_text_value":"Iwate Seiwa Hospital"},{"subitem_text_language":"en","subitem_text_value":"Health Administration Center, Iwate Medical University"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"open access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_abf2"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Ishikawa, Kazuyoshi","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"3433","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Nitatori, Tohru","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"3434","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Nakakarumai, Chihoko","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"3435","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Isobe, Naoko","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"3436","nameIdentifierScheme":"WEKO"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2016-12-27"}],"displaytype":"detail","filename":"KJ00008027239.pdf","filesize":[{"value":"3.1 MB"}],"format":"application/pdf","mimetype":"application/pdf","url":{"label":"KJ00008027239.pdf","objectType":"fulltext","url":"https://iwate-pu.repo.nii.ac.jp/record/1828/files/KJ00008027239.pdf"},"version_id":"2cf16cea-18bc-4f89-9078-b3fbd1fe2e73"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"C型肝炎","subitem_subject_language":"ja","subitem_subject_scheme":"Other"},{"subitem_subject":"ペグインターフェロン","subitem_subject_language":"ja","subitem_subject_scheme":"Other"},{"subitem_subject":"リバビリン","subitem_subject_language":"ja","subitem_subject_scheme":"Other"},{"subitem_subject":"HCV コア抗体","subitem_subject_language":"ja","subitem_subject_scheme":"Other"},{"subitem_subject":"副作用","subitem_subject_language":"ja","subitem_subject_scheme":"Other"},{"subitem_subject":"hepatitis C","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"peginterferon","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"ribavirin","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"anti-HCV core titer","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"side effects","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"departmental bulletin paper","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Serial changes of anti-HCV core titer in patients with chronic hepatitis C treated with peginterferon: a useful marker for outcome contributing to choice of an appropriate therapy","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Serial changes of anti-HCV core titer in patients with chronic hepatitis C treated with peginterferon: a useful marker for outcome contributing to choice of an appropriate therapy","subitem_title_language":"en"}]},"item_type_id":"7","owner":"16","path":["274"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2016-12-27"},"publish_date":"2016-12-27","publish_status":"0","recid":"1828","relation_version_is_last":true,"title":["Serial changes of anti-HCV core titer in patients with chronic hepatitis C treated with peginterferon: a useful marker for outcome contributing to choice of an appropriate therapy"],"weko_creator_id":"16","weko_shared_id":-1},"updated":"2025-08-04T04:21:09.025038+00:00"}